Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Congestive Heart Failure
Collaboration to develop AAV-based gene therapies for congestive heart failure
January 27th, 2005
Targeted Genetics Corp. (TGEN) and Celladon Corp. announced a collaboration agreement to develop adeno-associated virus (AAV)-based gene therapies for the treatment of congestive heart failure. Simultaneous with the initiation of this collaboration, Enterprise Partners and Venrock Associates, venture capital funds that have invested in Celladon, made a $6 million common stock investment in Targeted Genetics. The collaboration combines Targeted Genetics' expertise in the development, manufacture, and clinical evaluation of AAV-based therapies with Celladon's portfolio of genes with potential in the treatment of congestive heart failure. Under the...
Source: Women's Health Weekly (2005-01-27)
|
